Related Experiment Video
Updated: Feb 25, 2026
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
A novel HPV prophylactic peptide vaccine, designed by immunoinformatics and structural vaccinology approaches
Manica Negahdaripour1, Mahboobeh Eslami2, Navid Nezafat2
1Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; Pharmaceutical Sciences Research Center, Shiraz University of Medical Science, Shiraz, Iran.
Abstract:
Human papillomavirus (HPV)-caused cervical cancer is the fourth common female cancer globally. Despite availability of three effective vaccines in market, development of HPV prophylactic vaccines is still pursued due to affordability issues and type-restricted protection of the marketed vaccines. Investigational second generation prophylactic HPV vaccines are mostly exploiting epitopes from the virus minor capsid protein (L2), which despite many advantages suffer from low immunogenicity, a common problem of epitope vaccines. Adjuvants such as TLR agonists may overcome this drawback. In this study, different immunoinformatics and computational tools were employed to design a novel peptide vaccine for protection against cervical cancer. Two immunodominant epitope domains (amino acids 10-36 and 65-89) from the L2 protein of HPV 16 with potential to promote Th1, Th2, CTL, B-cell, and INF-gamma responses were selected. Flagellin, as a TLR5 agonist, a short synthetic TLR4 agonist, and two universal T-helper agonists (PADRE and TpD) were added to ensure strong induction of immune responses. Different segments were joined by proper linkers, and the physicochemical, structural, and immunological characteristics of the resultant construct were evaluated. Modeling, refinement, and validation were done to achieve a high quality 3D structure of the vaccine protein. Docking and molecular dynamics (MD) studies demonstrated an appropriate and stable interaction between the vaccine and TLR5 during the simulation period. Totally, a potential vaccine candidate with proper immunological and physicochemical properties was designed for HPV prophylaxis. The designed vaccine is expected to be capable of generating humoral and cellular responses, which are vital for protection against HPV.
Insights
A novel peptide vaccine was computationally designed for human papillomavirus (HPV) prophylaxis, targeting cervical cancer. This vaccine candidate incorporates L2 protein epitopes and immune-stimulating adjuvants to elicit robust humoral and cellular responses.
Area of Science:
- Immunology
- Vaccinology
- Computational Biology
Background:
- Cervical cancer, caused by human papillomavirus (HPV), is a significant global health concern for women.
- Existing HPV vaccines face challenges including cost and limited type coverage, necessitating new prophylactic vaccine development.
- Epitope-based vaccines, while promising, often exhibit low immunogenicity, a hurdle that adjuvants may address.
Purpose of the Study:
- To design a novel peptide vaccine candidate for human papillomavirus (HPV) prophylaxis against cervical cancer using immunoinformatics and computational approaches.
- To enhance vaccine immunogenicity by incorporating immunodominant L2 epitopes and potent immune-stimulating adjuvants.
Main Methods:
- Utilized immunoinformatics and computational tools to select and assemble HPV 16 L2 epitopes and universal T-helper epitopes.
- Integrated TLR agonists (Flagellin, TLR4 agonist) and PADRE/TpD to enhance immune response induction.
- Evaluated physicochemical, structural, and immunological properties; performed molecular modeling, refinement, validation, docking, and molecular dynamics studies.
Main Results:
- A novel peptide construct was designed by linking HPV 16 L2 epitopes (aa 10-36, 65-89) with adjuvants like Flagellin and universal T-helper epitopes.
- Computational analyses confirmed favorable physicochemical and structural properties, including a stable 3D structure.
- Molecular docking and dynamics simulations indicated stable interactions between the designed vaccine and TLR5.
Conclusions:
- A potential vaccine candidate for HPV prophylaxis was successfully designed with promising immunological and physicochemical characteristics.
- The designed vaccine is anticipated to induce both humoral and cellular immune responses crucial for protection against HPV infection and cervical cancer.
More Related Videos
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:51Vaccinations